Abstract | Objective: Methods: A prospective, parallel, randomized, placebo-controlled, and double-blind trial in 12 patients with CP was performed. End points were alterations in objective and subjective oral capacities after two BTX-A or corresponding placebo injections. Matched, healthy references were also evaluated. Results: The reference group demonstrated stronger and more efficient oral functions compared with the CP group. Subjective and objective oral capacities appeared to vary considerably between CP patients and also over time in this patient group and were poorly correlated. No significant effect of BTX-A compared with placebo on outcome variables was observed at group level, but continued treatment with BTX-A was requested by the majority of the patients. Conclusion: The evidence is unable to support the use of BTX-A for the treatment of affected masticatory muscles in CP, but the findings are inconclusive in certain respects. Larger, more homogeneous groups of CP patients need to be evaluated in future trials.
|
Authors | Birgitta Johansson Cahlin, Christopher Lindberg, Lars Dahlström |
Journal | Clinical and experimental dental research
(Clin Exp Dent Res)
Vol. 5
Issue 5
Pg. 460-468
(10 2019)
ISSN: 2057-4347 [Electronic] United States |
PMID | 31687178
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | ©2019 The Authors. Clinical and Experimental Dental Research published by John Wiley & Sons Ltd. |
Chemical References |
- Neuromuscular Agents
- Botulinum Toxins, Type A
|
Topics |
- Adult
- Botulinum Toxins, Type A
(therapeutic use)
- Bruxism
(drug therapy, pathology)
- Case-Control Studies
- Cerebral Palsy
(drug therapy, pathology)
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Injections, Intramuscular
- Male
- Masticatory Muscles
(drug effects)
- Middle Aged
- Neuromuscular Agents
(therapeutic use)
- Prognosis
- Prospective Studies
|